TG Therapeutics (TGTX) Competitors $32.20 +1.25 (+4.04%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends TGTX vs. TEVA, BGNE, MRNA, VTRS, SMMT, GMAB, RDY, SRPT, CTLT, and PCVXShould you be buying TG Therapeutics stock or one of its competitors? The main competitors of TG Therapeutics include Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Moderna (MRNA), Viatris (VTRS), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Catalent (CTLT), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry. TG Therapeutics vs. Teva Pharmaceutical Industries BeiGene Moderna Viatris Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Sarepta Therapeutics Catalent Vaxcyte Teva Pharmaceutical Industries (NYSE:TEVA) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, valuation and community ranking. Does the media refer more to TEVA or TGTX? In the previous week, Teva Pharmaceutical Industries had 20 more articles in the media than TG Therapeutics. MarketBeat recorded 27 mentions for Teva Pharmaceutical Industries and 7 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 1.31 beat Teva Pharmaceutical Industries' score of 0.61 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 12 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of TEVA or TGTX? 54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are owned by company insiders. Comparatively, 10.5% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more risk & volatility, TEVA or TGTX? Teva Pharmaceutical Industries has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.25, suggesting that its stock price is 125% more volatile than the S&P 500. Do analysts rate TEVA or TGTX? Teva Pharmaceutical Industries presently has a consensus price target of $20.88, suggesting a potential downside of 5.50%. TG Therapeutics has a consensus price target of $40.67, suggesting a potential upside of 26.29%. Given TG Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe TG Therapeutics is more favorable than Teva Pharmaceutical Industries.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has preferable valuation & earnings, TEVA or TGTX? TG Therapeutics has lower revenue, but higher earnings than Teva Pharmaceutical Industries. TG Therapeutics is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$16.77B1.49-$559M-$0.85-25.99TG Therapeutics$264.79M18.93$12.67M-$0.10-322.00 Does the MarketBeat Community favor TEVA or TGTX? Teva Pharmaceutical Industries received 670 more outperform votes than TG Therapeutics when rated by MarketBeat users. However, 76.57% of users gave TG Therapeutics an outperform vote while only 67.81% of users gave Teva Pharmaceutical Industries an outperform vote. CompanyUnderperformOutperformTeva Pharmaceutical IndustriesOutperform Votes132767.81% Underperform Votes63032.19% TG TherapeuticsOutperform Votes65776.57% Underperform Votes20123.43% Is TEVA or TGTX more profitable? TG Therapeutics has a net margin of -5.42% compared to Teva Pharmaceutical Industries' net margin of -5.73%. Teva Pharmaceutical Industries' return on equity of 42.92% beat TG Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-5.73% 42.92% 7.25% TG Therapeutics -5.42%-8.32%-3.40% SummaryTG Therapeutics beats Teva Pharmaceutical Industries on 11 of the 18 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get TG Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TGTX vs. The Competition Export to ExcelMetricTG TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.01B$6.57B$5.02B$9.08BDividend YieldN/A3.09%4.87%4.20%P/E Ratio-321.9710.55135.2017.16Price / Sales18.93194.011,120.31115.67Price / Cash362.0257.1640.5837.88Price / Book30.385.104.754.78Net Income$12.67M$151.51M$118.50M$225.60M7 Day Performance0.56%-2.13%-1.85%-1.21%1 Month Performance-7.31%-3.14%11.27%3.09%1 Year Performance87.76%11.54%29.92%16.48% TG Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TGTXTG Therapeutics4.3117 of 5 stars$32.20+4.0%$40.67+26.3%+87.1%$5.01B$264.79M-321.97290Positive NewsTEVATeva Pharmaceutical Industries1.8805 of 5 stars$16.66+1.0%$19.67+18.0%+112.2%$18.87B$16.77B-19.7937,851Analyst DowngradeOptions VolumeNews CoverageBGNEBeiGene2.6115 of 5 stars$176.52-1.6%$253.69+43.7%+0.7%$17.20B$2.46B-21.7710,600MRNAModerna4.2664 of 5 stars$41.59-0.6%$79.50+91.2%-54.3%$16.00B$5.06B-7.195,600Analyst DowngradeVTRSViatris2.0581 of 5 stars$12.71+0.6%$13.67+7.5%+19.8%$15.17B$15.05B-17.0738,000News CoverageSMMTSummit Therapeutics3.2652 of 5 stars$18.71+4.9%$33.33+78.2%+636.9%$13.80B$700,000.00-63.68105News CoverageGMABGenmab A/S4.2355 of 5 stars$20.14-0.1%$45.20+124.4%-33.5%$13.33B$19.84B19.582,204Positive NewsHigh Trading VolumeRDYDr. Reddy's Laboratories1.8457 of 5 stars$14.75+2.0%$17.00+15.3%+15.8%$12.31B$299.87B22.9527,048Analyst DowngradeNews CoverageSRPTSarepta Therapeutics4.8116 of 5 stars$126.12+1.9%$178.71+41.7%+31.8%$12.05B$1.64B98.971,314Analyst ForecastCTLTCatalent2.7788 of 5 stars$63.48+0.7%$63.40-0.1%N/A$11.52B$4.38B-27.9116,900High Trading VolumePCVXVaxcyte1.6049 of 5 stars$90.59+3.3%$147.50+62.8%+45.4%$11.29BN/A-19.07160Analyst ForecastInsider Trade Related Companies and Tools Related Companies Teva Pharmaceutical Industries Alternatives BeiGene Alternatives Moderna Alternatives Viatris Alternatives Summit Therapeutics Alternatives Genmab A/S Alternatives Dr. Reddy's Laboratories Alternatives Sarepta Therapeutics Alternatives Catalent Alternatives Vaxcyte Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TGTX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TG Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TG Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TGTX Stock Alerts